COVID-19 Vaccine Development
- Biopharmaceutical Development on COVID:19
COVID-19 vaccine development has facilitated through unparalleled collaboration in the pharmaceutical industry and between governments. The geographic distribution of COVID-19 vaccine development puts North American entities having about 40% of the activity compared to 30% in Asia and Australia, 26% in Europe, and a few projects in South America and Africa
The safety requirements for COVID-19 vaccines are the same as for any other vaccine and will not be lowered in the context of the pandemic. After development, the vaccines will continue to be carefully monitored for safety and effectiveness
Committee Members
Bartolome Ribas Ozonas
Royal National Academy of Pharmacy, Spain
Ernst Wagner
Ludwig-Maximilians-Universitat Munich, Germany
John K Maesaka
NYU Long Island School of Medicine, United States
Thomas J. Webster
Hebei University of Technology, China PDDS 2023 Speakers
Wayne Kaesemeyer
Augusta Hypertension PC, United States
Richard Z. Cheng
Cheng Integrative Health Center, United States
Mario Souza Y Machorro
International College of Superior Education, Mexico
Gurpreet Singh
Freyr Lifesciences Limited, United Kingdom
Liberata Sportiello
University of Campania “L. Vanvitelli”, Italy
Ravi P. Sahu
Wright State University, United StatesSubmit your abstract Today
Title : New approach to hyponatremia yields high prevalence and identification of natriuretic protein that causes renal salt wasting (RSW) and new syndrome of RSW in alzheimer’s disease
John K Maesaka, NYU Long Island School of Medicine, United States
Title : Synergism in the permeability of the blood Brain barrier between heavy metals and electromagnetic fields
Bartolome Ribas Ozonas, Royal National Academy of Pharmacy, Spain
Title : Chameleon nanocarriers for dynamic delivery of RNA Medicines
Ernst Wagner, Ludwig-Maximilians-Universitat Munich, Germany
Title : Mucoadhesive electrospun fibers in oral drug delivery
Luis Jesus Villarreal Gomez, Universidad Autonoma de Baja California, Mexico
Title : Human nanomedicine: Emphasizing results of nanomaterials in humans
Thomas J. Webster, Hebei University of Technology, China
Title : Qualitative and quantitative measures of drugs’ placenta permeability - A chromatographic and computational approach
Anna Weronika Sobanska, Medical University of Lodz, Poland
Title : Manufacturing outlook on cell and Gene and aseptic processing according the EU GMP Annex 1
Richard Denk, SKAN AG, Switzerland
Title : Multi-detection of pharmaceutical contamination in environment
Andreia Freitas, INIAV and REQUIMTE, Portugal
Title : New approaches to inhibit miRNAs in an atherosclerosis pre-clinical model
Noemi Rotllan Vila, IIB SANT PAU and CIBERDEM, Spain
Title : The role of non-antibiotic drugs on the development of antibiotic resistance
Mujde Eryilmaz, Ankara University, Turkey